Investors' belief that Chemclin Diagnostics will underperfor...

Investors' belief that Chemclin Diagnostics will underperform the broader market in the near future and its three-year earnings trends being worse than market expectations are contributing to its low P/E ratio. Unless conditions improve, the share price may remain at these levels.